Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres

Francesco Autore, MD, Nicola Piccirillo, MD, Andrea Nozza, MD, Idanna Innocenti, MD PhD, Rossana Putzulu, MD, Patrizia Chiusolo, MD, Federica Sora, MD, Gina Zini, MD PhD, Andrea Bacigalupo, MD, Luca Castagna, MD, Simona Sica, MD, Stefania Bramanti, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5692.

https://doi.org/10.1182/blood-2018-99-118554

Published: 2018

Journal Articles

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Vittorio Montefusco, MD, Alessandro Corso, MD, Monica Galli, MD PhD, Elena Tagliabue, Sara Pezzatti, Francesca Patriarca, MD, Filippo Gherlinzoni, MD, Renato Zambello, MD, Simona Sammassimo, Magda Marcatti, MD, Andrea Nozza, Claudia Crippa, MD, Anna Maria Cafro, MD, Luca Baldini, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 836.

https://doi.org/10.1182/blood.V130.Suppl_1.836.836

Published: 2017

Journal Articles

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Paola Tacchetti, MD, Lucia Pantani, MD, Valerio De Stefano, MD, Elena Zamagni, MD, Jacopo Peccatori, MD, Annalisa Pezzi, Statistician, Catello Califano, MD, Andrea Nozza, MD, Patrizia Tosi, MD, Carolina Terragna, PhD, Fabrizio Ciambelli, MD, Delia Cangini, MD, Piero Galieni, MD, Clotilde Cangialosi, MD, Giovanni De Sabbata, MD, Francesca Elice, MD, Antonio Palumbo, MD, Michele Cavo, MD

Blood (2014) 124 (21): 196.

https://doi.org/10.1182/blood.V124.21.196.196

Published: 2014

Journal Articles

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Blood (2012) 120 (21): 2971.

https://doi.org/10.1182/blood.V120.21.2971.2971

Published: 2012

Journal Articles

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Blood (2012) 120 (1): 9–19.

https://doi.org/10.1182/blood-2012-02-408898

Published: 2012

Includes: Supplemental data

Journal Articles

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Blood (2011) 118 (21): 1821.

https://doi.org/10.1182/blood.V118.21.1821.1821

Published: 2011

Journal Articles

Pilot Study with Lenalidomide in Patients with POEMS Syndrome

Andrea Nozza, MD, Fabrizia Terenghi, Rita Mazza, Eduardo Nobile Orazio, Fausto Adami, Giampaolo Merlini, MD, Chiara Briani, Giovanni Palladini, Mariella Grasso, Sara Gandolfi, MD, Carmelo Carlo-Stella, MD, Armando Santoro

Blood (2011) 118 (21): 4612.

https://doi.org/10.1182/blood.V118.21.4612.4612

Published: 2011

Journal Articles

Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis

Francesca Patriarca, Hermann Einsele, Francesco Spina, Benedetto Bruno, Chiara Nozzoli, Miriam Isola, Alessandra Sperotto, Andrea Nozza, Fortunato Morabito, Gernot Stuhler, Moreno Festuccia, Alberto Bosi, Renato Fanin, Paolo Corradini, MD

Blood (2010) 116 (21): 3534.

https://doi.org/10.1182/blood.V116.21.3534.3534

Published: 2010

Journal Articles

Melphalan 200 mg/m 2 versus melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

Blood (2010) 115 (10): 1873–1879.

https://doi.org/10.1182/blood-2009-09-241737

Published: 2010

Journal Articles

The Association of a Salvage Treatment Containing Novel Agents Followed by Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimen Improves Overall Survival and Time-to-Progression in Multiple Myeloma Patiens Relapsing After Autologous Stem Cell Transplantation: A Multicentric Retrospective Study Based On Donor Availability.

Francesca Patriarca, MD, Hermann Einsele, MD, Francesco Spina, MD, Chiara Nozzoli, MD, Andrea Nozza, MD, Alessandra Sperotto, MD, Fortunato Morabito, MD, Gernot Stuhler, Stefan Knop, Michela Cerno, MD, Alberto Bosi, MD, Renato Fanin, MD, Paolo Corradini, MD

Blood (2009) 114 (22): 4320.

https://doi.org/10.1182/blood.V114.22.4320.4320

Published: 2009

Journal Articles

A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.

Blood (2009) 114 (22): 492.

https://doi.org/10.1182/blood.V114.22.492.492

Published: 2009

Journal Articles

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Antonella Anastasia, MD, Monica Balzarotti, Massimo Magagnoli, MD, Michele Spina, MD, Rita Mazza, MD, L. Castagna, Andrea Nozza, Stefania Bramanti, md, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro

Blood (2009) 114 (22): 1213.

https://doi.org/10.1182/blood.V114.22.1213.1213

Published: 2009

Journal Articles

Melphalan 200 Mg/m 2 (Mel200) Versus Melphalan 100 Mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study

Blood (2008) 112 (11): 3316.

https://doi.org/10.1182/blood.V112.11.3316.3316

Published: 2008

Journal Articles

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Blood (2008) 112 (11): 1662.

https://doi.org/10.1182/blood.V112.11.1662.1662

Published: 2008

Journal Articles

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (Mel200) Versus Melphalan 100 mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients.

Blood (2007) 110 (11): 727.

https://doi.org/10.1182/blood.V110.11.727.727

Published: 2007

Journal Articles

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Antonio Palumbo, MD, Sara Bringhen, MD, Maria Teresa Petrucci, MD, Antonietta Falcone, MD, Anna Marina Liberati, MD, Mariella Grasso, MD, Francesco Pisani, MD, Tommaso Caravita, MD, Patrizia Pregno, MD, Andrea Nozza, MD, Paola Omedè, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Robin Foà, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 55.

https://doi.org/10.1182/blood.V108.11.55.55

Published: 2006

Journal Articles

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

Monica Balzarotti, MD, Michele Spina, MD, Massimo Magagnoli, MD, Teodoro Chisesi, MD, Antonello Pinto, MD, Luca Castagna, MD, Monica Demarco, MD, Mariagrazia Michieli, MD, Andrea Nozza, MD, Umberto Tirelli, MD, Armando Santoro, MD

Blood (2005) 106 (11): 2091.

https://doi.org/10.1182/blood.V106.11.2091.2091

Published: 2005

NARROW

Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres

Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study

Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Pilot Study with Lenalidomide in Patients with POEMS Syndrome

Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis

Melphalan 200 mg/m 2 versus melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Melphalan 200 Mg/m 2 (Mel200) Versus Melphalan 100 Mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study

Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (Mel200) Versus Melphalan 100 mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients.

A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m 2 (MEL200) Versus Melphalan 100 mg/m 2 (MEL100) in Newly Diagnosed Myeloma Patients.

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only